The overall safety profile of adalimumab use in rheumatoid arthritis is favorable, with the most common adverse reactions being infections, injection site itching, headache, and skeletal muscle pain. Adalimumab is a tumor necrosis factor (TNF)-alpha antagonist, and methotrexate is used in combination for the treatment of moderately to severely active rheumatoid arthritis in adults in whom methotrexate has not been effective, and for severely active ankylosing spondylitis in adults in whom conventional therapy has not been effective. The most common adverse reactions are infections (nasopharyngitis, upper respiratory tract infections), injection site reactions (erythema, itching, pain, or swelling), headache, and skeletal muscle pain. Hematologic reactions (pancytopenia), neurologic reactions (demyelinating lesions of central and peripheral nerves), and malignant neoplasms (leukemias, lymphomas) may also occur. It is contraindicated in people who are allergic to the components of the drug, people suffering from severe infectious diseases, people with moderate to severe heart failure, etc. Note that before, during and after the use of this product, patients must be closely monitored for the development of infections, either chronic active or focal active infections, and treatment with this product should not be initiated until the infection has been controlled. Adalimumab should be used in accordance with medical advice, regular checkups, and avoid self-medication.